Predictive Nature of Total Cholesterol Threshold: Possible Link to Suicidal Behavior
NCT02847741, Not applicable, Unknown, University Hospital, Montpellier
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Predictive Nature of Total Cholesterol Threshold: Possible Link to Suicidal Behavior | ClinicalTrials.gov |
| NCT number | NCT02847741 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 555 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University Hospital, Montpellier | ClinicalTrials.gov |
| Conditions | Current Major Depressive Disorder | ClinicalTrials.gov |
| Interventions | patient's routine care | ClinicalTrials.gov |
| First posted | 2016-07-28 | ClinicalTrials.gov |
| Last updated | 2016-07-28 | ClinicalTrials.gov |
Registered outcomes 41
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | frequency of suicide attempts | at 18 month | frequency of suicide attempts during the 18months follow-up, according to the total cholesterol threshold at baseline. The biological sampling is carried out after 12 hours of fasting. | ClinicalTrials.gov |
| Secondary | number of past SB | at 18 month | Studying the relation between the number of past SB (assessed by the Columbia Suicide History Form) and the occurrence of new SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | moral pain | at 18 month | Studying the relation between moral pain (assessed by Likert scale from 0 to 10) at baseline and the occurrence of new SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | physical pain | at 18 month | Studying the relation between physical pain (assessed Likert scale from 0 to 10) at baseline and the occurrence of new SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | suicidal ideation | at 18 month | Studying the relation between suicidal ideation (assessed by the Columbia Suicide Severity Rating Scale, the Scale of Suicidal Ideation) and the occurrence of new SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | depression (Quick Inventory of Depressive Symptomatology) | at 18 month | Studying the relation between score to the Quick Inventory of Depressive Symptomatology and the occurrence of new SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | history of childhood abuse | at 18 month | Studying the relation between an history of childhood abuse (assessed by the Childhood Trauma Questionnaire) and the occurrence of new SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | National Adult Reading Test score | at 18 month | Studying the relation between NART score (assessment of intellectual level) and the occurrence of new SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | scores to California Verbal Learning Test | at 18 month | Studying the relation between scores to California Verbal Learning Test (assessment of verbal memory) and the occurrence of SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | scores to Iowa Gambling Task Time frame: 18 months | at 18 month | Studying the relation between scores to the Iowa Gambling Task (assessment of decision making) and the occurrence of new SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | score to the brixton test | at 18 month | Studying the relation between score to the brixton test (assessment of mental flexibility) and the occurrence of SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | scores to verbal fluency | at 18 month | Studying the relation between scores to verbal fluency and the occurrence of SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | scores to Reversal Learning Task | at 18 month | Studying the relation between scores to Reversal learning task (assessment of decision making) and the occurrence of new SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | scores to the Attentional Stroop test | at 18 month | Studying the relation between scores to Attentional Stroop test and the occurrence of new SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | relation between inflammatory markers and the occurrence of SB | at 18 month | Studying the relation between inflammatory markers at baseline and the occurrence of new SB during the 18 months follow- | ClinicalTrials.gov |
| Secondary | relation between thyroid function and the occurrence of SB | at 18 month | Studying the relation between thyroid function at baseline and the occurrence of new SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | relation between lipid profile and the occurrence of SB | at 18 month | Studying the relation between lipid profile at baseline and the occurrence of new SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | relation between pharmacological assays and the occurrence of SB | at 18 month | Studying the relation between pharmacological assays at baseline and the occurrence of new SB during the 18 months follow-up | ClinicalTrials.gov |
| Secondary | relation between the characteristic of the mood depressive disorder (unipolar or bipolar depression) and the predictive or vulnerability factors of SB | at 18 month | Studying the potential specificity of predictive or vulnerability factors of SB depending on whether the diagnosis is unipolar or bipolar depression | ClinicalTrials.gov |
| Secondary | the characteristic of past SB | at 18 month | Studying the relation between the number and the lethality of past SB (assessed by the Columbia Suicide History Form, the Risk Rescue Rating Scale, the Suicidal Intent Scale ) and the response to antidepressant treatment during the 18 months follow-up | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Iowa Gambling Lite | Secondary outcome | ConductCognition |
| Probabilistic Reversal Learning | Secondary outcome | ConductCognition |
| Rule Anticipation Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)